Trump announces trade deal with EU following months of negotiations
Christopher J. Joyce, the Chief Legal and Administrative Officer at Alignment Healthcare, Inc. (NASDAQ:ALHC), a $3.3 billion healthcare company whose stock has surged 258% over the past year, recently sold shares of the company’s common stock valued at approximately $294,262. The transactions took place over two days, March 18 and March 19, 2025. According to InvestingPro analysis, the stock is currently trading near its 52-week high of $17.27.
On March 18, Joyce sold 6,725 shares at a weighted-average price of $16.8906 per share. The following day, March 19, he sold an additional 7,057 shares at a weighted-average price of $16.088 per share and 3,959 shares at a weighted-average price of $16.9588 per share. The prices for these transactions ranged from $15.73 to $17.12 per share. InvestingPro data shows the company has achieved remarkable momentum with a 52.8% return year-to-date, despite operating at a loss with -$0.67 earnings per share.
These sales were conducted to cover tax withholding obligations related to the vesting of restricted stock units and the grant of immediately vested common stock. As such, they do not represent discretionary trades by Joyce. Following these transactions, he retains ownership of 440,022 shares of Alignment Healthcare. Discover more insights about ALHC’s valuation and 11 additional key ProTips with a subscription to InvestingPro.
In other recent news, Alignment Healthcare reported its fourth-quarter 2024 earnings, surpassing expectations with an EPS of -0.16 against the forecast of -0.18. The company also exceeded revenue projections, reporting $701.2 million compared to the anticipated $674.97 million, marking a significant achievement. For the full year, Alignment Healthcare’s total revenue reached $2.7 billion, reflecting a 48% increase year-over-year. Looking ahead, the company has issued 2025 revenue guidance of $3.72 billion to $3.78 billion, indicating a projected 40% growth at the midpoint.
Analysts have shown confidence in the company’s growth prospects, with Raymond (NSE:RYMD) James raising its price target to $19 and maintaining a Strong Buy rating. Piper Sandler also increased its price target to $21 while keeping an Overweight rating. Both firms noted Alignment Healthcare’s strong performance and growth strategies as key factors in their positive outlook. Additionally, the company’s membership grew by approximately 59% in 2024, with significant expansion outside California, contributing to its promising future. The company also achieved its first year of adjusted EBITDA profitability, further enhancing its financial position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.